We responded to the House of Commons Science and Technology Committee’s ‘Brexit science and innovation Summit’ consultation. Our response focused on regulation. We voiced our concerns on the future availability and safety of medicines and devices in the UK. The Committee discussed outcomes of the consultation at the Summit on 22 February 2018. Regulation was a key part of these discussions.
Published: 06 Feb 2018 in